Despite extensive research, the prognosis of advanced pancreatic cancer remains poor. Because gemcitabine is superior to bolus 5-fluorouracil (5-FU), with a response rate of 5% and a median overall survival (OS) of 5.7 months ([@bib1]), combination therapy with gemcitabine and cytotoxic drugs or molecular-targeted agents has been intensely investigated. Only erlotinib in combination with gemcitabine showed a statistically significant but clinically small improvement in OS ([@bib10]), but most phase III clinical trials have failed to demonstrate significant differences in OS. Recently, the efficacy of multiagent regimens was reported in two randomised controlled trials ([@bib21]; [@bib2]); however, multiagent regimens have potentially increased adverse effects.

S-1 is an oral fluoropyrimidine consisting of tegafur, a prodrug of 5-FU, and two biochemical modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate, with single-agent activity in advanced pancreatic cancer and an objective response rate (ORR) comparable to that for gemcitabine monotherapy ([@bib25]; [@bib19]). Combination chemotherapy with gemcitabine and S-1 is reportedly well tolerated and active against advanced pancreatic cancer ([@bib15], [@bib16]; [@bib24]; [@bib8]; [@bib9]; [@bib18]). Initially, combination chemotherapy with gemcitabine and S-1 was reported as a 3-week regimen, but our modified 4-week regimen demonstrated a time to progression of 10.0 months and OS of 20.4 months with mild adverse effects in patients with advanced pancreatic cancer ([@bib13]).

Here, we conducted a multicentre, randomised phase II trial of gemcitabine alone *vs* combination therapy with gemcitabine and S-1 in patients with advanced pancreatic cancer.

Patients and methods
====================

Trial design
------------

This multicentre, open-label randomised phase II trial was conducted at six centres in Japan. The protocol was approved by the institutional review board at each centre. Informed consent was obtained from each participant. The study, which was registered in the UMIN Clinical Trials Registry (UMIN000000498), was conducted according to the Declaration of Helsinki. The primary trial end point was progression-free survival (PFS). The secondary end points were OS, ORR, and safety.

Eligibility
-----------

The eligibility criteria were as follows: (1) pancreatic adenocarcinoma diagnosed by pathological examination or typical radiographic findings; (2) unresectable locally advanced or metastatic disease; (3) no prior treatment for pancreatic cancer including surgery or radiation therapy; (4) Eastern Cooperative Oncology Group (ECOG) performance status of 0--2; (5) age \>20 years; (6) capability of oral intake; (7) life expectancy \>12 weeks; and (8) adequate organ function, as indicated by a white blood cell count \>3000 per mm^3^, platelet count \>100 000 per mm^3^, haemoglobin \>10.0 g dl^−1^, serum creatinine \<1.5 times the normal upper limit, creatine clearance \>50 ml per min, total bilirubin \<2 times the normal upper limit, and aspartate aminotransferase and alanine aminotransferase levels \<5 times the normal upper limit. The exclusion criteria were as follows: (1) severe complications, such as active infection, cardiac or renal disease, marked pleural effusion, or ascites; (2) active gastrointestinal bleeding; (3) severe drug hypersensitivity; (4) active concomitant malignancy; and (5) pregnancy or lactation.

Randomisation
-------------

Patients were randomly assigned to each treatment arm on a 1 : 1 basis according to a computer-generated minimisation method, stratified by enrolling centre and extent of disease (locally advanced *vs* metastatic).

Treatment
---------

Patients randomly allocated to the gemcitabine arm received gemcitabine intravenously at 1000, mg m^−2^ over 30 min on days 1, 8, and 15 of each 4-week cycle. Patients randomly allocated to the gemcitabine and S-1 arm received gemcitabine intravenously at 1000, mg m^−2^ over 30 min on days 1 and 15 and S-1 orally twice daily for 2 weeks followed by a 2-week rest between each 4-week cycle. Three doses of S-1 were established according to the body surface area (BSA) as follows: BSA ⩽1.25 m^2^, 80 mg per day; 1.25 m^2^\<BSA⩽1.5 m^2^, 100 mg per day; and BSA ⩾1.5 m^2^, 120 mg per day. All treatments were given until disease progression, unacceptable toxic effects, or withdrawal of consent.

Assessments
-----------

Tumour responses were measured by computed tomography, which was performed at baseline, and then every two cycles (8 weeks); tumour responses were evaluated using the Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 ([@bib23]). CA19-9 levels were measured at baseline and at each cycle.

Adverse events and dose modification
------------------------------------

All adverse events were evaluated at each cycle according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 (see <http://ctep.cancer.gov/reporting/ctc.html>). Treatment was temporarily suspended in the case of grade 3/4 haematological toxicity or grade 2 or higher non-haematological toxicity. After recovery to grade 1 toxicity or lower, treatment was restarted at the following reduced doses. In the gemcitabine arm, gemcitabine was reduced by 200 mg m^−2^. In the gemcitabine and S-1 arm, S-1 was reduced to: BSA ⩽1.25 m^2^, 50 mg per day; 1.25 m^2^\<BSA ⩽1.5 m^2^, 80 mg per day; and BSA ⩾1.5 m^2^, 100 mg per day. When dose reduction was necessary after the reduction of S-1, gemcitabine was reduced by 200 mg m^−2^. No dose escalation was allowed following dose reduction.

Statistics
----------

The primary end point hypothesis used for sample-size estimation was that combination therapy with gemcitabine and S-1 would increase the median PFS by 2 months (from 3 to 5 months) compared with gemcitabine monotherapy with a type I error probability of 5% (one-sided) and power of 80%. The required number of patients was 50 and a 5% dropout was accounted for in the sample-size calculation. The OS from randomisation was calculated from the date of randomisation to the date of death from any cause or censored at the last follow-up. The PFS was calculated from the date of randomisation to the date of either disease progression or death or censored at the last follow-up. The OS and PFS were estimated using the Kaplan--Meier method, and were compared between treatment arms using the log-rank test. A Cox proportional hazards model was used to estimate the hazard ratios with a 95% confidence interval (CI). The ORRs were reported as best achieved response rates. Proportions between the arms were compared using the *χ*^2^ test or Fisher\'s test; quantitative variables were compared using Student\'s *t*-test or the Wilcoxon test. All analyses were conducted based on the intention-to-treat principle. Two-sided *P*-values \<0.05 were considered to be significant. The final analysis was based on follow-up information, which was collected until February 2011. JMP 8.0 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.

Results
=======

Patients
--------

A total of 106 patients were randomly assigned in six hospitals in Japan between July 2006 and February 2009. The patients\' characteristics are shown in [Table 1](#tbl1){ref-type="table"}. The baseline characteristics were well balanced between the two arms. The study flow diagram is shown in [Figure 1](#fig1){ref-type="fig"}. One patient in the gemcitabine arm and two patients in the gemcitabine and S-1 arm received no study drug. All 106 patients were assessable for OS, PFS, and response; 103 patients were assessable for safety.

At the time of analysis, six patients (two in the gemcitabine arm and four in the gemcitabine and S-1 arm) were still alive. The total number of cycles was 277 and 328 in the gemcitabine and gemcitabine plus S-1 arms, respectively. The median follow-up period was 10.0 months.

Efficacy
--------

The ORR according to RECIST 1.0 ([Table 2](#tbl2){ref-type="table"}) was 18.9% (95% CI: 10.6--31.4%) in the gemcitabine and S-1 arm, compared with 9.4% (95% CI: 4.9--20.3%) in the gemcitabine arm (*P*=0.265). Only one patient in the gemcitabine and S-1 arm had a complete response. The median response duration was 10.0 months in the gemcitabine and S-1 arm and 10.6 months in the gemcitabine arm. The disease control rate of 79.2% in the gemcitabine and S-1 arm was significantly higher than that (56.6%) in the gemcitabine arm (*P*=0.021). [Table 2](#tbl2){ref-type="table"} summarises our efficacy results.

The median PFS ([Figure 2](#fig2){ref-type="fig"}) for combination therapy with gemcitabine and S-1 was 5.4 months (95% CI: 3.7--9.4 months) while that for gemcitabine monotherapy was 3.6 months (95% CI: 2.0--5.1 months). Combination therapy with gemcitabine and S-1 demonstrated a significantly improved PFS over gemcitabine monotherapy, with a hazard ratio of 0.64 (95% CI: 0.42--0.97; *P*=0.036).

The median OS was 13.5 months (95% CI: 7.8--16.3 months) in the gemcitabine and S-1 arm and 8.8 months (95% CI: 7.0--10.6 months) in the gemcitabine arm ([Figure 3](#fig3){ref-type="fig"}). The 1-year survival rate was 52.8% in the gemcitabine and S-1 arm and 30.2% in the gemcitabine arm (*P*=0.031). The improvement in OS did not reach statistical significance, with a hazard ratio of 0.72 (95% CI: 0.48--1.07; *P*=0.104).

Median PFS and OS in locally advanced disease are 12.6 *vs* 8.1 months and 23.9 *vs* 11.0 months in gemcitabine and S-1 arm *vs* gemcitabine arm, respectively. Meanwhile, median PFS and OS in metastatic disease are similar (4.0 *vs* 2.4 months) and (8.9 *vs* 7.9 months), respectively ([Table 2](#tbl2){ref-type="table"}).

*Post hoc* subgroup analysis with a Karnofsky performance status (KPS) score of 100 showed that combination therapy with gemcitabine and S-1 demonstrated a longer OS of 15.0 months (95% CI: 8.9--23.9 months), compared with 8.5 months (95% CI: 7.0--11.0 months) for gemcitabine monotherapy (*P*=0.011). Meanwhile, in patients with a KPS \<100, no significant difference was found in OS of 6.8 months (95% CI: 3.7--15.4 months) in the gemcitabine and S-1 arm and 8.8 months (95% CI: 5.0--11.3 months) in the gemcitabine arm (*P*=0.997).

Eight patients without pathological diagnosis were included in our study. There were no differences in OS between patients with and without pathological diagnosis (10.0 *vs* 10.1 months, *P*=0.982). When patients with pathological diagnosis were analysed, PFS was 5.4 *vs* 2.9 months (*P*=0.011) and OS was 15.0 *vs* 8.2 months (*P*=0.022) in gemcitabine and S-1 arm *vs* gemcitabine arm.

The treatment after study drug failure was selected at the discretion of the individual investigator. No patients with locally advanced disease received chemoradiation therapy after study drug failure. Second-line chemotherapy was administered to 31 patients (58.5%) in the gemcitabine arm and 18 (34.0%) in the gemcitabine and S-1 arm, respectively (*P*=0.019). Notably, S-1 was administered alone or as combination therapy in all 31 gemcitabine-failure patients receiving second-line chemotherapy. Overall survival after the introduction of second-line chemotherapy was 5.0 and 5.3 months in the gemcitabine and gemcitabine plus S-1 arms, respectively (*P*=0.296). The regimens of chemotherapy after study drug failure are shown in [Figure 4](#fig4){ref-type="fig"}. The number of administered drugs during the clinical course was ⩾2 in 58.5% *vs* 96.2%, ⩾3 in 15.1% *vs* 34.0%, and 4 in 3.8% *vs* 9.4% in the gemcitabine and gemcitabine plus S-1 arms, respectively.

Safety and dose intensity
-------------------------

Treatment-related adverse events are shown in [Table 3](#tbl3){ref-type="table"}. The overall number of grade 3 or greater toxicities did not increase in the gemcitabine and S-1 arm (53.8% in the gemcitabine arm and 43.1% in the gemcitabine and S-1 arm). Neutropenia was the most frequent grade 3 or greater toxicity in both arms. Non-haematological grade 3 or greater toxicities were infrequent in both groups, but stomatitis, diarrhoea and rash were more often seen in the gemcitabine and S-1 arm. No chemotherapy-related death occurred.

The mean dose intensity for gemcitabine was 618.2 mg m^−2^ per week (82.4% of the planned dose) in the gemcitabine arm and 489.0 mg m^−2^ per week (97.8% of the planned dose) in the gemcitabine and S-1 arm. The mean dose intensity for S-1 was 251.4 mg m^−2^ per week (89.8% of the planned dose) in the gemcitabine and S-1 arm.

Discussion
==========

In the present randomised phase II trial, combination therapy with gemcitabine and S-1 demonstrated a longer median PFS and higher 1-year survival rate with similar severe adverse effects compared with gemcitabine monotherapy. The addition of S-1 to gemcitabine led to a 4.7-month improvement in the median OS; however, this result was not statistically significant.

Combination therapy with gemcitabine and other cytotoxic drugs or molecular-targeted agents has been thoroughly investigated in patients with pancreatic cancer, but no significant improvement in OS has been confirmed in a single, randomised controlled trial, except for combination therapy with gemcitabine and erlotinib ([@bib10]). However, the improvement in OS was modest with a median survival of 6.24 months for combination therapy with gemcitabine and erlotinib *vs* 5.91 months for gemcitabine monotherapy. In a meta-analysis, capecitabine, an oral fluoropyrimidine similar to S-1, in combination with gemcitabine, was shown to improve OS compared with gemcitabine alone with a hazard ratio of 0.86 ([@bib3]). Recently, [@bib2] reported a significantly longer OS with FORFIRINOX than gemcitabine alone in patients with metastatic pancreatic cancer. Thus, fluoropyrimidine is currently a key drug in the treatment of advanced pancreatic cancer. In adjuvant settings ([@bib17]), the OS with 5-FU plus folinic acid was as effective as gemcitabine. S-1 is also an oral fluoropyrimidine that has been reported to be active against pancreatic cancer. We previously reported promising data for combination therapy with gemcitabine and S-1 using a 4-week schedule ([@bib13]). This subsequent randomised controlled trial demonstrated a significantly longer PFS (the primary end point) and higher 1-year survival rate. Despite an improvement in OS of 4.7 months with a hazard ratio of 0.72 for combination therapy with gemcitabine and S-1, this difference did not reach statistical significance. In a *post hoc* analysis of patients with a KPS of 100, the median OS was significantly longer in patients treated with gemcitabine and S-1 (15.0 *vs* 8.5 months; *P*=0.011). The trend toward improved results with combination therapy in patients with a good performance status was also reported for combination therapy with gemcitabine and capecitabine ([@bib5]). By contrast, OS with gemcitabine monotherapy showed similar results regardless of the KPS score in our study (8.5 months with KPS=100 *vs* 8.8 months with KPS \<100).

The problem often encountered with randomised controlled trials of combination therapy with gemcitabine and other drugs is the crossover to experimental drugs in the gemcitabine arm. In our study, 31 patients (58.5%) in the gemcitabine monotherapy arm received S-1 as second-line chemotherapy. In Japan, both gemcitabine and S-1 are approved for the treatment of pancreatic cancer and are widely used in clinical practice. Therefore, patients in gemcitabine arm had easy access to S-1 as second-line treatment. Although second-line chemotherapy has not been established in patients with gemcitabine-refractory pancreatic cancer, S-1 has been reported to be useful in this setting ([@bib11]; [@bib22]). This crossover might obscure the efficacy of combination therapy with gemcitabine and S-1 over gemcitabine monotherapy. As S1 improved the prognosis of advanced pancreatic cancer using a historical cohort design ([@bib12], [@bib14]), the introduction of new effective drugs could lead to improved survival even in patients with pancreatic cancer refractory to gemcitabine. In addition to gemcitabine and S-1, oxaliplatin ([@bib7]) and irinotecan were administered to refractory patients in the present study. However, drugs other than gemcitabine and S-1 were not approved for treatment of pancreatic cancer and were administered only as clinical trials. As a result, the introduction rate of second-line treatment was lower in gemcitabine and S-1 arm compared with gemcitabine arm (34.0% *vs* 58.5%). The rate of patients receiving three or four anticancer drugs was higher in the combination therapy arm. As shown for colorectal cancer ([@bib4]), the availability of multiple drugs might be associated with prolonged survival in pancreatic cancer. Thus, the development of multiple effective drugs and appropriate combination regimens is as important as randomised controlled trials of first-line chemotherapy.

Given the palliative role of chemotherapy in patients with advanced pancreatic cancer, safety is as important as efficacy. Our 4-week regimen of combination therapy with gemcitabine and S-1 did not significantly increase the overall severe toxicity. This regimen allowed a biweekly hospital visit compared with three times a month for gemcitabine monotherapy, which could also decrease the treatment burden for incurable patients. In this sense, FORFIRINOX ([@bib2]), the first regimen without gemcitabine that was demonstrated to be superior to gemcitabine, was associated with severe toxicities, including febrile neutropenia.

Some limitations to our study exist. First, the sample size (106 patients) was relatively small. Although combination therapy with gemcitabine and S-1 achieved the primary end point of PFS and improved the median OS duration by 4.7 months, this difference in OS did not reach statistical significance. At the Annual meeting of the American Society of Clinical Oncology 2011, two other randomised controlled trials of gemcitabine alone *vs* gemcitabine and S-1 combination therapy were reported ([@bib6]; [@bib20]). While one phase II trial ([@bib20]) demonstrated significant superiority of combination arm in ORR, time-to-progression and OS, the other large phase III trial ([@bib6]) showed significantly longer PFS, but failed to demonstrate superiority in OS. The results might differ because the schedule and planned dose intensity were somewhat different in these three trials. Given the failure of one phase III trial, another large scale phase III trial is necessary to confirm the survival benefit of this combination therapy but we should select patients who are most likely to benefit from combination therapy, that is, better PS. In addition, the best dose intensity should be considered in those study population. Second, our 4-week regimen was safely administered to patients with advanced pancreatic cancer without a significant increase in overall severe toxicity compared with gemcitabine monotherapy, but the planned dose intensity was lower than the 3-week regimen used in other studies ([@bib15], [@bib16]; [@bib24]). This difference in dose intensity might influence the efficacy of the gemcitabine and S-1 arm, although our 4-week regimen showed high tolerability with a relatively high actual dose intensity.

In conclusion, this randomised trial demonstrated a longer PFS and higher 1-year survival rate for combination therapy with gemcitabine and S-1 in patients with advanced pancreatic cancer. Overall survival was also significantly longer in patients with a good performance status (KPS=100). Thus, a large-scale, phase III randomised controlled trial is warranted.
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###### Patient characteristics

                                          **Gemcitabine (*****n*****=53)**   **Gemcitabine and S-1 (*****n*****=53)**   ***P*****-value**
  --------------------------------------- ---------------------------------- ------------------------------------------ -------------------
  *Age, years*                                                                                                          
   Median (range)                         67 (42--84)                        63 (40--82)                                0.200
                                                                                                                         
  *Sex,* n (%)                                                                                                          
   Male                                   33 (62.3%)                         42 (79.2%)                                 0.087
   Female                                 20 (37.8%)                         11 (20.8%)                                  
                                                                                                                         
  *ECOG performance status,* n (%)                                                                                      
   0                                      32 (60.4%)                         31 (58.5%)                                 0.843
   1                                      20 (37.7%)                         22 (41.5%)                                  
   2                                      1 (1.9%)                           0                                           
                                                                                                                         
  *Karnofsky performance status,* n (%)                                                                                 
   100                                    18 (34.0%)                         27 (50.9%)                                 0.131
   90                                     29 (54.7%)                         21 (39.6%)                                  
   80                                     3 (5.7%)                           5 (9.4%)                                    
   70                                     2 (3.8%)                           0                                           
   60                                     1 (1.9%)                           0                                           
                                                                                                                         
  *Disease extent,* n (%)                                                                                               
   Locally advanced                       13 (24.5%)                         15 (28.3%)                                 0.668
   Metastatic                             40 (75.5%)                         38 (71.7%)                                  
                                                                                                                         
  *Site of primary tumour,* n (%)                                                                                       
   Head                                   18 (34.0%)                         20 (37.7%)                                 0.850
   Body                                   12 (22.6%)                         10 (18.9%)                                  
   Tail                                   23 (43.4%)                         23 (43.4%)                                  
                                                                                                                         
  *Site of metastasis,* n (%)                                                                                           
   Liver                                  25 (47.2%)                         24 (45.3%)                                 1.000
   Lung                                   3 (5.7%)                           1 (1.9%)                                   0.618
   Lymph node                             20 (37.7%)                         21 (39.6%)                                 1.000
   Peritoneum                             10 (18.9%)                         7 (13.2%)                                  0.598
   Biliary stent, n (%)                   22 (41.5%)                         17 (32.1%)                                 0.421
                                                                                                                         
  *CA19-9, IU l*^−*1*^                                                                                                  
   Median (range)                         1204 (1--465 511)                  822 (1--130 800)                           0.800

Abbreviation: ECOG=Eastern Cooperative Oncology Group.

###### Efficacy results

                                                          **Gemcitabine (*****n*****=53)**   **Gemcitabine and S-1 (*****n*****=53)**   ***P*****-value**
  ------------------------------------------------------- ---------------------------------- ------------------------------------------ -------------------
  *Best response,* n (%)                                                                                                                
   Complete response                                      0                                  1 (1.9%)                                    
   Partial response                                       5 (9.4%)                           9 (17.0%)                                   
   Stable disease                                         25 (47.2%)                         32 (60.4%)                                  
   Progressive disease                                    21 (39.6%)                         9 (17.0%)                                   
   Not evaluable                                          2 (3.8%)                           2 (3.8%)                                    
   Response rate                                          9.4%                               18.9%                                      0.265
   Disease control rate                                   56.6%                              79.2%                                      0.021
                                                                                                                                         
  *Median progression-free survival, months (95*% *CI)*                                                                                 
   Overall                                                3.6 (2.0--5.1)                     5.4 (3.7--9.4)                             0.035
   Locally advanced                                       8.1 (2.2--13.0)                    12.6 (3.4--16.5)                           0.112
   Metastatic                                             2.4 (1.9--3.9)                     4.0 (3.6--5.5)                             0.099
                                                                                                                                         
  *Median overall survival, months (95*% *CI)*                                                                                          
   Overall                                                8.8 (7.0--10.6)                    13.5 (7.8--16.3)                           0.102
   Locally advanced                                       11.0 (5.8--23.6)                   23.9 (13.5--26.4)                          0.297
   Metastatic                                             7.9 (5.0--9.5)                     8.9 (6.3--14.2)                            0.311
                                                                                                                                         
  One-year survival rate                                  30.2%                              52.8%                                      0.031

Abbreviation: CI=confidence interval.

###### Adverse events

                              **Gemcitabine (*****n*****=52)**   **Gemcitabine and S-1 (*****n*****=51)**               
  -------------------------- ---------------------------------- ------------------------------------------ ------------ ------------
  *Haematological*                                                                                                      
   Neutropenia                           32 (61.5%)                             18 (34.6%)                  29 (56.9%)   17 (33.3%)
   Febrile neutropenia                    1 (1.9%)                               1 (1.9%)                       0            0
   Anaemia                               43 (82.7%)                             6 (11.5%)                   40 (78.4%)   6 (11.8%)
   Thrombocytopenia                      35 (67.3%)                              1 (1.9%)                   30 (58.8%)    2 (3.9%)
                                                                                                                              
  *Non-haematological*                                                                                                  
   Fatigue                               25 (48.1%)                              2 (3.8%)                   20 (39.2%)    1 (2.0%)
   Anorexia                              27 (51.9%)                              5 (9.6%)                   32 (62.7%)    2 (3.9%)
   Nausea                                18 (34.6%)                                 0                       18 (35.3%)    1 (2.0%)
   Vomiting                              9 (17.3%)                                  0                       9 (17.6%)        0
   Constipation                          26 (50.0%)                              1 (1.9%)                   19 (37.3%)    1 (2.0%)
   Diarrhoea                             6 (11.5%)                                  0                       17 (33.3%)    1 (2.0%)
   Elevated liver function               24 (46.2%)                             7 (13.5%)                   25 (49.0%)    4 (7.8%)
   Stomatitis                             5 (9.6%)                                  0                       13 (25.5%)    3 (5.9%)
   Rash                                   5 (9.6%)                                  0                       11 (21.6%)    2 (3.9%)
   GI haemorrhage                            0                                      0                        2 (3.9%)     2 (3.9%)
   Pneumonitis                               0                                      0                        1 (2.0%)     1 (2.0%)
   Taste alteration                       1 (1.9%)                                  0                        3 (5.9%)        0
   Alopecia                               2 (3.8%)                                  0                        1 (2.0%)        0
   Peripheral oedema                      1 (1.9%)                                  0                        2 (3.9%)        0
   Pruritus                                  0                                      0                        1 (2.0%)        0
                                                                                                                              
  Any grade 3--4                                                                28 (53.8%)                               22 (43.1%)

Abbreviation: GI=gastrointestinal.

The data are shown as value (%).
